Indrani Lall Franchini - 21 Jul 2021 Form 4 Insider Report for ALEXION PHARMACEUTICALS, INC.

Role
EVP, Chief Compliance Officer
Signature
/s/ Douglas J. Barry, Attorney-in-Fact for Indrani L. Franchini
Issuer symbol
N/A
Transactions as of
21 Jul 2021
Net transactions value
-$2,520,023
Form type
4
Filing time
23 Jul 2021, 16:37:55 UTC
Previous filing
16 Jul 2021
Next filing
09 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALXN Common Stock, par value $.0001 per share Disposed to Issuer $0 -116,075 -100% $0.000000* 0 21 Jul 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALXN Option to Purchase Common Stock Disposed to Issuer $2,520,023 -25,165 -100% $100.14 0 21 Jul 2021 Common Stock, par value $.0001 per share 25,165 $100.14 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Indrani Lall Franchini is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Represents shares of Alexion common stock disposed in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 12, 2020, by and among Alexion and AstraZeneca PLC. In accordance with the Merger Agreement, upon the First Effective Time (as defined in the Merger Agreement), each share of Alexion common stock was converted into the right to receive (i) 2.1423 American Depositary Shares (ADSs) of AstraZeneca PLC and (ii) $60.00 in cash (the "Merger Consideration").
F2 Upon the First Effective Time, these options were cancelled and converted into the right to receive the product obtained by multiplying (A) the excess, if any, of the value of the Merger Consideration over the exercise price per share of the Alexion common stock subject to such options immediately prior to the First Effective Time by (B) the number of shares of Alexion common stock subject to such option immediately prior to the First Effective Time by (ii) the value of the Merger Consideration.